Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

User discusses hair regrowth using RU58841, minoxidil, and dutasteride. Many users praise the progress and ask about the treatments' effectiveness and side effects.

A user shared their successful experience with hair regrowth and transitioning from male to female using minoxidil, finasteride, Nutrafol, microneedling, and hormone replacement therapy (HRT). They expressed gratitude for the results and encouraged others to explore treatments that align with their personal goals.

The user reported significant hair regrowth and stopped hair loss after using Pyrilutamide and Minoxidil for four months. They found Pyrilutamide effective in blocking DHT locally without side effects, preferring a gray market version over Koshine's product.